logo

ALEC

AlectorยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ALEC Profile

Alector, Inc.

A clinical-stage biotech company pioneering immuno-neurology and innate immuno-oncology

Biological Technology
--
02/07/2019
NASDAQ Stock Exchange
238
12-31
Common stock
131 Oyster Point Blvd, Suite 600 , South San Francisco, California 94080
--
Alector, Inc., originally incorporated as a limited liability company in Delaware in May 2013, is a clinical-stage biopharmaceutical company. Pioneering Immunoneurology, a new treatment for neurodegeneration. Immunoneurology identifies immune dysfunction as the underlying cause of a variety of pathologies that are drivers of degenerative encephalopathy. They are developing therapies designed to counteract these conditions at the same time by restoring healthy immune function to the brain.